Literature DB >> 19296468

MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3.

Florin M Selaru1, Alexandru V Olaru, Takatsugu Kan, Stefan David, Yulan Cheng, Yuriko Mori, Jian Yang, Bogdan Paun, Zhe Jin, Rachana Agarwal, James P Hamilton, John Abraham, Christos Georgiades, Hector Alvarez, Perumal Vivekanandan, Wayne Yu, Anirban Maitra, Michael Torbenson, Paul J Thuluvath, Gregory J Gores, Nicholas F LaRusso, Ralph Hruban, Stephen J Meltzer.   

Abstract

UNLABELLED: Cholangiocarcinomas (CCAs) are aggressive cancers, with high mortality and poor survival rates. Only radical surgery offers patients some hope of cure; however, most patients are not surgical candidates because of late diagnosis secondary to relatively poor accuracy of diagnostic means. MicroRNAs (miRs) are involved in every cancer examined, but they have not been evaluated in primary CCA. In this study, miR arrays were performed on five primary CCAs and five normal bile duct specimens (NBDs). Several miRs were dysregulated and miR-21 was overexpressed in CCAs. miR-21 differential expression in these 10 specimens was verified by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). To validate these findings, qRT-PCR for miR-21 was then performed on 18 additional primary CCAs and 12 normal liver specimens. MiR-21 was 95% sensitive and 100% specific in distinguishing between CCA and normal tissues, with an area under the receiver operating characteristic curve of 0.995. Inhibitors of miR-21 increased protein levels of programmed cell death 4 (PDCD4) and tissue inhibitor of metalloproteinases 3 (TIMP3). Notably, messenger RNA levels of TIMP3 were significantly lower in CCAs than in normals.
CONCLUSIONS: MiR-21 is overexpressed in human CCAs. Furthermore, miR-21 may be oncogenic, at least in part, by inhibiting PDCD4 and TIMP3. Finally, these data suggest that TIMP3 is a candidate tumor suppressor gene in the biliary tree.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296468      PMCID: PMC3124086          DOI: 10.1002/hep.22838

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

3.  Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Authors:  Yonatan Y Mahller; Sachin S Vaikunth; Maria C Ripberger; William H Baird; Yoshinaga Saeki; Jose A Cancelas; Timothy M Crombleholme; Timothy P Cripe
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

4.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

5.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.

Authors:  I A Asangani; S A K Rasheed; D A Nikolova; J H Leupold; N H Colburn; S Post; H Allgayer
Journal:  Oncogene       Date:  2007-10-29       Impact factor: 9.867

6.  MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.

Authors:  Yannick Ladeiro; Gabrielle Couchy; Charles Balabaud; Paulette Bioulac-Sage; Laura Pelletier; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

7.  miR-21 microRNA expression in human gastric carcinomas and its clinical association.

Authors:  Shih-Hsuan Chan; Chew-Wun Wu; Anna F Y Li; Chin-Wen Chi; Wen-Chang Lin
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

8.  Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer.

Authors:  O Slaby; M Svoboda; P Fabian; T Smerdova; D Knoflickova; M Bednarikova; R Nenutil; R Vyzula
Journal:  Oncology       Date:  2008-01-15       Impact factor: 2.935

9.  MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Heike Varnholt; Uta Drebber; Falko Schulze; Inga Wedemeyer; Peter Schirmacher; Hans-Peter Dienes; Margarete Odenthal
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.

Authors:  Fabio Petrocca; Rosa Visone; Mariadele Rapazzotti Onelli; Manisha H Shah; Milena S Nicoloso; Ivana de Martino; Dimitrios Iliopoulos; Emanuela Pilozzi; Chang-Gong Liu; Massimo Negrini; Luigi Cavazzini; Stefano Volinia; Hansjuerg Alder; Luigi P Ruco; Gustavo Baldassarre; Carlo M Croce; Andrea Vecchione
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

View more
  130 in total

1.  Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.

Authors:  Arti B Gaur; Susan L Holbeck; Nancy H Colburn; Mark A Israel
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

3.  miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Steve F Bronk; Rory L Smoot; Christian D Fingas; Nathan W Werneburg; Lewis R Roberts; Justin L Mott
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

Review 4.  microRNA deregulation in keloids: an opportunity for clinical intervention?

Authors:  Xin Yu; Zheng Li; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-10-21       Impact factor: 6.831

Review 5.  New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphoma.

Authors:  Xin Yu; Zheng Li
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

6.  MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways.

Authors:  Bo Gong; Wan-Wei Liu; Wen-Jing Nie; Dong-Feng Li; Zi-Jun Xie; Chao Liu; Yan-Hui Liu; Ping Mei; Zi-Jun Li
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

7.  miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice.

Authors:  Zhipeng Meng; Xianghui Fu; Xiaosong Chen; Samuel Zeng; Yan Tian; Richard Jove; Rongzhen Xu; Wendong Huang
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

Review 8.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

9.  miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Authors:  Jing Zhang; Jingjing Jiao; Silvia Cermelli; Kyle Muir; Kwang Hwa Jung; Ruhai Zou; Asif Rashid; Mihai Gagea; Sonya Zabludoff; Raghu Kalluri; Laura Beretta
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

Review 10.  MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Takatsugu Kan; Stephen J Meltzer
Journal:  Curr Opin Pharmacol       Date:  2009-09-19       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.